PRINCETON, NJ - Oct 3, 2017 - Artificial intelligence could acclaim a new era for drug development however forethought continues about how revolutionary its touch will actually be

The recent deal from the Top 10 Pharma MNC ($43m deal with British Artificial intelligence firm) may signal a revolution for drug development that could accelerate the drug discovery process, helping patients in urgent need of specialized treatments. Also many other players looking at investments in the AI arena on the expectation those AI solutions are braced to shape new the biopharma industry.

In the similar manner that the financial sector has engaged physicists and mathematicians to originate prognostic software to tweak trading decisions, many professionals foretell that Life sciences industry will be particularly centripetal to Artificial intelligence (AI) solutions as its inherent stranding in science, design and invention.